Pain Mediation By Innocuous Sensory Afferents Expression of protein kinase Cγ (PKCγ) in interneurons of lamina II of the spinal cord dorsal horn is thought to be essential for mechanical allodynia, a painful response to normally innocuous stimuli. Nonpeptidergic nociceptors were initially assumed to innervate PKCγ interneurons, because they terminate in the same sublamina. Neumann et al. now show that the terminals of nonpeptidergic nociceptor afferents terminate dorsal to the PKCγ interneurons, with only minimal overlap.
Source: www.medicalnewstoday.comFDA Accepts Streamlined Phase 3 Development Plan For Q8003IR 'Dual Opioid' Pain Therapy QRxPharma Limited (ASX: QRX; OTCQX: QRXPY), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapies for pain and central nervous system (CNS) disorders, announced today that the U.S.
Source: www.medicalnewstoday.comCara Therapeutics Announces Successful Completion Of Phase I Clinical Trial Of Novel Analgesic, CR845 Cara Therapeutics, Inc. announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of acute and chronic pain. The drug candidate was safe and well-tolerated after intravenous infusion, and resulted in plasma levels of CR845 expected to be associated with clinical analgesic activity.
Source: www.medicalnewstoday.com
# posted by Network @ 9:00 AM
